Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: quidditch who wrote (2808)	5/17/1999 4:21:00 PM
From: Biomaven	Read Replies (2) \| Respond to of 10280

steven, I think you have to distinguish between the onset of action, where there clearly was enough power to show that Nori beats Claritin, and overall efficacy, where there was clearly not enough to distinguish between the two. I should have been clearer that I was referring to the latter. To demonstrate a statistical difference between the two in efficacy after say a week you would require an enormous trial. It's tough enough to nail down that a given drug is better than a placebo - showing that it is definitively better than an already approved drug is considerably harder. Mostly when drug companies are trying to show one drug is "better" than another they focus on issues like drug interactions, side effects and frequency of dosage. This is obviously always going to be an issue for SEPR. My guess is that it will be rare that they will actually ever be able to demonstrate better efficacy for their ICE. However if you can demonstrate comparable efficacy with an improved side effect or dosage profile you can still dominate. A good example is Ranitidine(Zantac) vs. Cimetidine - here a (somewhat) better side-effect profile for Zantac served to nearly wipe out the already entrenched Tagamet, despite a pricing disadvantage. Peter